Form 4: BioCardia Director Jim L. Allen Granted Stock Options
Insider Transaction Report
BioCardia Director Jim L. Allen was granted 12,000 stock options with an exercise price of $1.37, vesting over one year.
Summary
- Director Jim L. Allen of BioCardia, Inc. was granted 12,000 stock options.
- The options have an exercise price of $1.37 per share.
- The 12,000 stock options will vest 100% on the one-year anniversary of the grant date (December 8, 2025), becoming exercisable on December 8, 2026, provided Mr. Allen continues as a service provider.
- The options expire on December 8, 2035.
- Following this transaction, Mr. Allen beneficially owns a total of 15,313 derivative securities.
Sentiment
Score: 6
Explanation: The grant of stock options to a director is a standard compensation practice, aligning the director's interests with long-term shareholder value, indicating routine corporate governance.
Positives
- The grant of 12,000 stock options to Director Jim L. Allen aligns his interests with long-term shareholder value.
- The options have a 10-year expiration date, providing a sustained long-term incentive for the director.
Future Outlook
The stock options are subject to a one-year vesting period, contingent on the reporting person's continued service to the company, providing a future incentive for performance.
Industry Context
This filing is a routine disclosure of insider trading activity and does not provide broader industry context or trends.
Related Party Transactions
- Grant of 12,000 stock options to Jim L. Allen, a Director of BioCardia, Inc., as part of his compensation package.
Stakeholder Impact
- Shareholders: Potential for increased alignment of Director Jim L. Allen's interests with long-term shareholder value through equity incentives.
Next Steps
- The granted stock options will vest on December 8, 2026, subject to Director Jim L. Allen's continued service to BioCardia, Inc.
Key Dates
| Date | Description |
|---|---|
| 12/08/2025 | Grant date of 12,000 stock options to Director Jim L. Allen. |
| 12/10/2025 | Date the Statement of Changes in Beneficial Ownership (Form 4) was signed. |
| 12/08/2026 | One-year anniversary of the grant date, when 100% of the granted stock options are scheduled to vest and become exercisable, subject to continued service. |
| 12/08/2035 | Expiration date of the granted stock options. |
Recommendation
holdThis Form 4 filing reports a routine stock option grant to a director, which is a standard compensation practice and does not provide new information that would alter the fundamental investment thesis for BioCardia, Inc. Therefore, a 'hold' recommendation is appropriate based solely on this filing.
Keywords
BioCardia, BCDA, stock options, insider transaction, director compensation, equity grant, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.